Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Legal Status  





2 See also  





3 References  














AM-2233






Српски / srpski
Srpskohrvatski / српскохрватски
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


AM-2233
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • NZ: Temporary Class
  • UK: Class B
  • Identifiers
    • 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole

    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.233.382 Edit this at Wikidata
    Chemical and physical data
    FormulaC22H23IN2O
    Molar mass458.343 g·mol−1
    3D model (JSmol)
    • Ic3ccccc3C(=O)c1cn(CC2CCCCN2C)c4c1cccc4

    • InChI=1S/C22H23IN2O/c1-24-13-7-6-8-16(24)14-25-15-19(17-9-3-5-12-21(17)25)22(26)18-10-2-4-11-20(18)23/h2-5,9-12,15-16H,6-8,13-14H2,1H3 checkY

    • Key:KSLCYQTUSSEGPT-UHFFFAOYSA-N checkY

     ☒NcheckY (what is this?)  (verify)

    AM-2233 is a drug that acts as a highly potent full agonist for the cannabinoid receptors, with a Ki of 1.8 nM at CB1 and 2.2 nM at CB2 as the active (R) enantiomer.[1] It was developed as a selective radioligand for the cannabinoid receptors and has been used as its 131I derivative for mapping the distribution of the CB1 receptor in the brain.[2][3][4][5][6][7] AM-2233 was found to fully substitute for THC in rats, with a potency lower than that of JWH-018 but higher than WIN 55,212-2.[8]

    It is notable for inducing tinnitus,[9] though the reasons for this are unclear and may provide valuable insight into tinnitus research.

    Legal Status[edit]

    As of October 2015 AM-2233 is a controlled substance in China.[10]

    See also[edit]

    References[edit]

    1. ^ Hongfeng Deng (2000). Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs (PhD Dissertation). University of Connecticut. ProQuest 304624325.
  • ^ Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, et al. (October 2005). "Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor". Journal of Medicinal Chemistry. 48 (20): 6386–6392. doi:10.1021/jm050135l. PMID 16190764.
  • ^ Hanuš LR, Mechoulam R (2005). "Cannabinoid chemistry: an overview". Cannabinoids as Therapeutics. Milestones in Drug Therapy MDT. pp. 23–46. doi:10.1007/3-7643-7358-X_2. ISBN 978-3-7643-7055-8.
  • ^ Shen CP, Xiao JC, Armstrong H, Hagmann W, Fong TM (February 2006). "F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist". European Journal of Pharmacology. 531 (1–3): 41–46. doi:10.1016/j.ejphar.2005.12.026. PMID 16438957.
  • ^ Dhawan J, Deng H, Gatley SJ, Makriyannis A, Akinfeleye T, Bruneus M, et al. (August 2006). "Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233". Synapse. 60 (2): 93–101. doi:10.1002/syn.20277. PMID 16715483. S2CID 21269336.
  • ^ Leung K (Dec 12, 2006). "R-2-[131I]Iodophenyl-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. PMID 20641836.
  • ^ Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, et al. (November 2008). "Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation". Chemistry & Biology. 15 (11): 1207–1219. doi:10.1016/j.chembiol.2008.10.011. PMC 3700404. PMID 19022181.
  • ^ Järbe TU, Deng H, Vadivel SK, Makriyannis A (September 2011). "Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats". Behavioural Pharmacology. 22 (5–6): 498–507. doi:10.1097/FBP.0b013e328349fbd5. PMC 3212432. PMID 21836461.
  • ^ "AM-2233 INDUCED TINNITUS: COLLECTED REPORTS". 30 September 2014. Retrieved 5 April 2019.
  • ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=AM-2233&oldid=1205102741"

    Categories: 
    Benzoylindoles
    AM cannabinoids
    Aminoalkylindoles
    Iodobenzene derivatives
    Piperidines
    Designer drugs
    Cannabinoid stubs
    Hidden categories: 
    CS1 Chinese-language sources (zh)
    Articles with short description
    Short description matches Wikidata
    Articles with changed CASNo identifier
    ECHA InfoCard ID from Wikidata
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugs missing an ATC code
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
    All stub articles
     



    This page was last edited on 8 February 2024, at 21:44 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki